Biocon Ltd. Announces Exclusive Licensing Agreement for Generic Ozempic (Semaglutide) Commercialization in Brazil with Biomm S.A.

Biocon Limited, an innovation-led global biopharmaceutical company, has signed an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialization of its vertically integrated drug product, Semaglutide, used to improve glycemic control in adults with type-2 diabetes. Biocon will be responsible for the development, manufacturing, and supply, while Biomm will handle regulatory approval and commercialization. Biomm is Brazil's first biotechnology-focused company, prioritizing partnerships to expand population access to advanced treatments for diabetes.